Name Your NET Hero to mark Worldwide NET Cancer Awareness Day, November 10th. Send in a photo of your NET Hero, and a line or two describing why he or she is your hero. Be it your doctor, nurse, spouse, friend, partner, colleague, etc., or all of them, bring these people to the spotlight, make their names and faces recognized on a global scale! Read More
NET Cancer Day 2013 Webinar
November 7, 2013
In recognition of Worldwide NET Cancer Awareness Day on November 10, NorCal CarciNet is hosting a one-hour, free webinar. Here’s a great opportunity to hear from 3 of the leading specialists in carcinoid/NET cancer treatment on NET CANCER DAY: Professor Dr. Richard P. Baum, Bad Berka, Germany; Dr. Eric Liu, Vanderbilt University, Tennessee; and Dr. Thomas O’Dorisio, University of Iowa. Read More
A Possible Cure for Neuroendocrine Cancer: Exciting Update!
June 21, 2013
Thanks to the enormously generous gift of about $2 million from Vincent Hamilton, founder and Chairman of the Board of Tethys Oil AB and the amazing iCancer campaign — the championing of the cause by Alexander Masters, Dominic Nutt and Liz Scarff in Europe and Catherine Cooling Davis in the United States – the oncolytic virus clinical trial at Uppsala University in Sweden is going to become a reality!! Read more
Neuroendocrine Cancer: Making Sense of the Disease
Carcinoid/NET Specialist Dr. Eric Liu to Speak in Dallas, Texas
May 31, 2013
"Neuroendocrine Cancer: Making Sense of the Disease" is a special presentation by Dr. Eric Liu, Director of the Neuroendocrine Center at Vanderbilt University Medical Center in Nashville, Tennessee, scheduled for June 8 at Baylor Hospital, hosted by the Carcinoid Cancer Texas Survivors Support Group. For more information, CLICK HERE.
Carcinoid Survivor Thrives as Endurance Rider
May 24, 2013
Monica Grundmann, who was diagnosed with goblet cell carcinoid in 2012, thought she had entered her last competitive event in June 2012. She won that OCTRA-sponsored Stormont Competitive Trail Ride, and dedicated her ride to the Carcinoid Cancer Foundation and the Carcinoid Neuroendocrine Tumor Society of Canada. Fortunately, it was not her last competitive event! Read moreabout Monica and her Morab stallion, Excalibur Legend, as they plan for an international competition this September and her dream to enter the World Equestrian Games in Bromont, Quebec in 2018.
Carcinoid/Neuroendocrine Tumor Presentations at ASCO Annual Meeting
May 22, 2013
Twenty-six abstracts about carcinoid and other NETs will be presented at the 2013 ASCO (American Society of Clinical Oncology) Annual Meeting, to be held May 31 to June 4 in Chicago, Illinois. Cutting-edge scientific presentations and comprehensive educational content will be shared with more than 25,000 oncology professionals from a broad range of specialties, exploring the theme of the Meeting — "Building Bridges to Conquer Cancer." Click here for the carcinoid/NETs presentations.
Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging Patient Program
May 22, 2013
Josh Mailman, President of the NorCal CarciNET support group and Chair of the Patient Advocate Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June 9th in Vancouver, British Columbia, Canada. The “Patient Program” provides a unique opportunity to network with passionate advocates and leading experts in neuroendocrine tumors (NETs), lymphoma disease, and dementia. Read more
Mayo Clinic Completes First Whole Exome Sequence of Small Intestine Neuroendocrine Tumors
May 17, 2013
Researchers at the Mayo Clinic in Rochester, Minnesota have completed the first whole exome sequence of small intestine neuroendocrine tumors and have identified six pathways as potential drug targets for these NETs. Read more about the Mayo Clinic research here. Click here for the full text article. And learn more about exome sequencing.
NANETS 2012 Early Career Development Award
March 28, 2013
Congratulations to Lauren Fishbein, MD, PhD, upon receiving NANETS’ 2012 Early Career Development Award! Dr. Fishbein’s research project is “Somatic Mutations in Pheochromocytoma and Paragangliomas.” According to Dr. Fishbein, “"Our hope is to determine if distinct patterns of somatic mutations are associated with different inherited mutations. Since pheochromocytomas and paragangliomas are tumors associated with high morbidity and mortality with limited treatments for recurrent or metastatic disease, it is critical to understand tumorigenesis [malignant transformation] in order to identify novel molecular markers for future therapeutic targets." The award of $50,000 is supported by Novartis with the goal of improving outcomes for NET patients.